On September 6, via Courtesy Trade Confirmation alert to subscribers, we confirmed the exit of our $
IBB position when it hit the official target price of $ 140.80.
Not exact matches
At the opening bell of last Friday's session, we sold our
position in iShares Nasdaq Biotech ($
IBB) for a modest gain.
We scratched on one
position ($ AMLN), and locked in small gains on the other two long
positions ($
IBB and $ LF).
Recently, the fund's three largest equivalent
positions were in the iShares Russell Mid-Cap Growth ETF (IWP; weight of about 41 %), iShares Nasdaq Biotechnology ETF (
IBB; 24 %), and Vanguard Energy ETF (VDE; 23.6 %).
The fund had top equivalent
positions in the Vanguard Information Technology ETF (VGT; average weight of 53.8 %), iShares North American Tech - Software ETF (IGV; 15.1 %), iShares North American Tech - Multimedia Networking ETF (IGN; 13.1 %), iShares S&P Mid-Cap 400 Value ETF (IJJ; 7.5 %), iShares Morningstar Small - Cap ETF (JKJ; 4.3 %), and iShares Nasdaq Biotechnology ETF (
IBB; 3.2 %).